Article info
PDFRecent advances in basic science
COVID-19 and immunomodulation in IBD
- Correspondence to Professor Markus F Neurath, First Department of Medicine and Deutsches Zentrum Immuntherapie DZI, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen 91052, Germany; markus.neurath{at}uk-erlangen.de
Citation
COVID-19 and immunomodulation in IBD
Publication history
- Received March 30, 2020
- Revised April 3, 2020
- Accepted April 3, 2020
- First published April 17, 2020.
Online issue publication
April 15, 2021
Article Versions
- Previous version (15 April 2021).
- Previous version (15 April 2021).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.